Compare Immunovant Inc. Common Stock (IMVT) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Matson Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Matson Inc trades at $229 (market cap $6.67B). The key difference: Immunovant Inc. Common Stock and Matson Inc are close in size by market cap, and Matson Inc pays a 0.68% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Matson Inc for 23 Days on average.
| IMVT | MATX | |
|---|---|---|
Market Cap | $6.62B | $6.67B |
Volume | 1,131,364 | 233,711 |
Sector | Health | Industrials |
52-Week High | $44.96 | $238.60 |
52-Week Low | $17.03 | $88.05 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $5.72B | $7.26B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Matson (MATX) trades at $222.92, down 0.83% today, with neutral technical signals and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats, including Q2 2026 EPS of $4.27 versus $3.79 expected. Revenue growth continues with 2026 projections reaching $3.5 billion, supported by a 13.4% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment.
MATX presents a compelling investment case with solid profitability metrics and analyst support, though near-term technical resistance at $224 may limit upside. The company's raised full-year outlook and consistent dividend payments provide stability, while exposure to freight market volatility remains a key risk factor for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
